IRB Number:

1109-04

Trial Status:

Open for Enrollment

Phase: III

Why is this study being done?

The purpose of this trial is to determine the effectiveness of celiac plexus neurolysis as an adjunct to standard medical therapy for pain control in patients with unresectable pancreatic cancer and moderate to severe pain.

Who is Eligible to Participate in the Study?

Unresectable or inoperable carcinoma of the pancreas as determined by CT or EUS. Presence of mid-abdominal pain at least 2 days per week, lasting at least 1 hour per day. No known coagulopathy as measured by PT (INR) of >1.5. Patient must not require more than 2 l/min oxygen supplementation. >4 weeks since previous surgery. Life expectancy > 3 months.

What is Involved With this Study?

Patients will have been scheduled for an endoscopic ultrasound to evaluate their pancreatic cancer. The research part of the study is the celiac plexus block. If the patient has "stage IV" pancreatic cancer, he/she will be randomly placed in one of two groups. One group receives the nerve block plus usual pain medications. The other group receives only the usual pain medications.

How long will the Study run?

Patients will be involved in this study for up to 7 months and will have about 5 visits to the clinic.

Who can I Contact for Additional Information on this Trial?

Complete Request Form for Cancer Clinical Trial Information at Mayo Clinic or
For more information on this study, please contact:

Jacksonville, FL site- Joy N. Hardee, Clinical Research Coordinator (904) 953-8456.

Scottsdale/ Phoenix, AZ site- Heather Stein, Clinical Research Coordinator (480)301-4976.

What is/are the Locations of this Clinical Trial?

• Jacksonville, FL
• Scottsdale and Phoenix, AZ

Last updated: 08/22/2006